Clinical trials: Cancer: Solid Tumors
C. Difficile Infection, Cancer
Safety of Stool Transplant for Patients With Difficult to Treat C. Difficile Infection
The purpose of this study is to test the safety of FMT in patients with C. difficile and cancer. In previous other studies, FMT has been shown to cure C.
- Trial name
- NCT02770326
- Testing
- Fecal Microbiota Transplantation (FMT)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Solid Tumours
A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours
This study will evaluate safety , clinical pharmacology and efficacy of intravenous RC88 combined with Sintilimab in advancedsolid tumours
- Trial name
- NCT05804526
- Testing
- RC88, Sintilimab Injection
- Where
- China
- Volunteers
- 82 people
- Sponsor
- RemeGen Co., Ltd.
Biliary Tract Cancer (BTC), Colorectal Cancer (CRC)
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
The purpose of this open-label nonrandomized Phase 1/2 study is to evaluate INCB001158 in combination with chemotherapy in participants with advanced/metastatic solid tumors.
- Conditions
- Biliary Tract Cancer (BTC), Colorectal Cancer (CRC), Endometrial Cancer, Gastroesophageal Cancer (GC)
- Trial name
- NCT03314935
- Testing
- INCB001158, Oxaliplatin, Leucovorin
- Where
- 10 sites in United States, Belgium and 1 more
- Volunteers
- 149 people
- Sponsor
- Incyte Corporation
Solid Tumor
Intratumoural Injection of a Novel NanoZolid®-Docetaxel Depot Formulation in Patients With Advanced Solid Tumours
This is a multicentre, open-label, first in man, study of a novel NanoZolid®-docetaxel depot formulation (NZ-DTX Depot) given as an intra-tumoural injection in patients with advanced solid tumours.
- Trial name
- NCT04810208
- Testing
- Docetaxel
- Where
- 4 sites in Denmark, Lithuania and 1 more
- Volunteers
- 6 people
- Sponsor
- Lidds AB
Solid Tumors and Hematologic Malignancy
A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients
This is an open-label, multicenter, non-randomized, dose escalation and tumor-expansion phase I trial to evaluate safety and tolerability of INCSHR01210 in patients with advanced solid tumors.
- Trial name
- NCT02492789
- Testing
- INCSHR01210 injection
- Where
- 5 sites in Australia
- Volunteers
- 49 people
- Sponsor
- Atridia Pty Ltd.
Advanced Solid Tumors
A Study of ASP2074 in Adults With Solid Tumors
ASP2074 is a potential new treatment for people with certain solid tumors. Before ASP2074 is available as a treatment, the researchers need to understand how it is processed by and acts upon the body.
- Trial name
- NCT05646797
- Testing
- ASP2074
- Where
- 13 sites in United States, Japan
- Volunteers
- 23 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Solid Tumour Refractory to Conventional Treatment
Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid Tumours
This study will investigate the use of a new drug targeting the DNA repair pathway AZD6738, an ATR inhibitor). Many tumours have lost important DNA repair functions and rely more heavily on a few remaining repair pathways to…
- Trial name
- Patriot (NCT02223923)
- Testing
- AZD6738, Palliative radiotherapy
- Where
- 3 sites in United Kingdom
- Volunteers
- 87 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Solid Tumor
A Prospective Study of the Relevance of the HLA-G Immune Checkpoint in Cancer Immunotherapy
Therapeutic targeting of immune checkpoints PD-1/PD-L1 and/or CTLA-4 is efficient in several solid cancer subtypes, however only some patients do experience clinical benefit from these treatments.
- Trial name
- GEIA (NCT04300088)
- Volunteers
- 281 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Unspecified Adult Solid Tumor
Holographic Mm-Wave Imaging in Patients Undergoing Radiation Therapy
This trial studies the quality of holographic mm-wave imaging in patients undergoing radiation therapy. Holographic mm-wave imaging is a common type of imaging used in airport body scanners that may be helpful in improving the…
- Trial name
- NCT03789773
- Testing
- Millimeter-Wave Holographic Imaging
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Southern California
Solid Tumor, Adult, Triple Negative Breast Cancer
AVID100 in Advanced Epithelial Carcinomas
Approximately 90 male and female patients with documented solid tumor malignancies of epithelial origin that are locally advanced or metastatic, and either refractory to standard therapy or for whom no standard therapy is…
- Conditions
- Solid Tumor, Adult, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT03094169
- Testing
- AVID100 IV
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Formation Biologics
Locally Advanced or Metastatic Pancreatic Cancer With
HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors
This study is a randomized, open-label, multicenter Phase II clinical trial designed to evaluate the Safety, Tolerability and Preliminary Efficacy of HRS-4642 Combination with Other Antitumor Therapies in Patients with Solid…
- Trial name
- NCT07296341
- Testing
- HRS-4642;Adebrelimab Injection; nab-paclitaxel; gemcitabine, HRS-4642;nab-paclitaxel; gemcitabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Neoplasm Malignant, Renal Cell Carcinoma
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination…
- Conditions
- Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
- Trial name
- STELLAR-001 (NCT03845166)
- Testing
- XL092, Atezolizumab, Avelumab
- Where
- 86 sites in United States, Australia and 8 more
- Volunteers
- 325 people
- Sponsor
- Exelixis
Oesophageal Cancer, Gastric Cancer
Modulated Mid-frequency Whole-body Electromyostimulation and Nutritional Therapy in Gastrointestinal Cancer Patients
The purpose of this study is to assess the efficacy of modulated mid-frequency whole-body electromyostimulation (WB-EMS) combined with nutritional therapy in patients with gastrointestinal cancer.
- Conditions
- Oesophageal Cancer, Gastric Cancer, Duodenal Cancer, Colorectal Cancer
- Trial name
- MOMENT (NCT06414122)
- Testing
- mid-frequency whole-body electromyostimulation (WB-EMS), conventional exercise training, nutritional therapy
- Where
- Germany
- Volunteers
- 88 people
- Sponsor
- University of Cologne
Ovarian Cancer, Colorectal Cancer
EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide
This study is looking at the safety and tolerability of the experimental biological drug EMD 273066 when given with low dose cyclophosphamide to patients with recurring EpCAM positive ovarian, prostate, colorectal or non-small…
- Conditions
- Ovarian Cancer, Colorectal Cancer, Carcinoma, Non-small-cell Lung, Prostate Cancer
- Trial name
- NCT00132522
- Testing
- EMD 273066
- Where
- 5 sites in United States, Switzerland
- Volunteers
- 45 people
- Sponsor
- EMD Serono
Rhabdomyosarcoma and Other Soft Tissue Sarcomas, Ewing's Sarcoma Family of Tumors
Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors
The purpose of this study is to determine the safest and most effective oral dose combinations of sorafenib and irinotecan in pediatric patients with solid tumors, i.e. relapsed or refractory.
- Conditions
- Rhabdomyosarcoma and Other Soft Tissue Sarcomas, Ewing's Sarcoma Family of Tumors, Osteosarcoma, Neuroblastoma
- Trial name
- NCT01518413
- Testing
- sorafenib, irinotecan
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- HMeany
Solid Tumor
Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)
The primary objective of this study is to assess the efficacy of Debio 1347 in terms of objective response rate (ORR) in participants with solid tumors harboring fibroblast growth factor receptor (FGFR)1-3 gene…
- Trial name
- NCT03834220
- Testing
- Debio 1347
- Where
- 105 sites in United States, Australia and 21 more
- Volunteers
- 63 people
- Sponsor
- Debiopharm International SA
Dyspnea, Pulmonary Complications
Buspirone in Reducing Shortness of Breath in Patients With Cancer
RATIONALE: Buspirone may be effective in reducing dyspnea (shortness of breath) in patients with cancer who are undergoing chemotherapy.
- Conditions
- Dyspnea, Pulmonary Complications, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00053846
- Testing
- buspirone hydrochloride
- Where
- 15 sites in United States
- Volunteers
- 432 people
- Sponsor
- University of Rochester
Graft Versus Host Disease, Unspecified Adult Solid Tumor, Protocol Specific
Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant
RATIONALE: Thalidomide may interfere with the body's ability to recognize transplanted bone marrow cells as foreign and may help treat patients with graft-versus-host disease.
- Conditions
- Graft Versus Host Disease, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00003894
- Testing
- thalidomide
- Where
- 10 sites in United States
- Volunteers
- 36 people
- Sponsor
- Roswell Park Cancer Institute
Solid Tumor
A Study of LY3405105 in Participants With Advanced Cancer
The main purpose of this study is to investigate the safety of LY3405105 in participants with advanced cancer. The study has two parts phase 1a and phase 1b. Participants will only enroll in one part.
- Trial name
- NCT03770494
- Testing
- LY3405105
- Where
- 17 sites in United States, Canada and 3 more
- Volunteers
- 54 people
- Sponsor
- Eli Lilly and Company
Solid Tumor
A Study of ASP3082 in Adults With Advanced Solid Tumors
This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP3082. The study aims to check how safe and well-tolerated ASP3082 is for people with advanced solid tumors…
- Trial name
- NCT05382559
- Testing
- Setidegrasib, Cetuximab, Leucovorin
- Where
- 68 sites in United States, China and 5 more
- Volunteers
- 681 people
- Sponsor
- Astellas Pharma Inc
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.